Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interferon labeling

Executive Summary

Avonex (interferon beta-1a) marketer Biogen expects to meet with FDA in the second quarter regarding the agency's proposal for an interferon class black box warning. "Alpha interferon is used at different dosing ranges and is used to treat patients with different diseases than multiple sclerosis, so it is conceivable that the safety profile will differentiate from that of the beta interferon," VP-Medical Research Burt Adelman, MD, said April 12. FDA notified alpha and beta interferon manufacturers that the warning should be similar to that found in labeling for Schering-Plough's Peg-Intron (1"The Pink Sheet" March 5, In Brief)
Advertisement

Related Content

Interferon labeling
Interferon labeling
Advertisement
UsernamePublicRestriction

Register

PS037662

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel